Minocin is an antibacterial drug owned by Rempex and its active ingredient is minocycline hydrochloride.
The generic version of Minocin, based on the expiration date of its last patent, is expected to be available after 12 May, 2031. This is subject to any successful Para IV filings that may result in an earlier generic release.
Minocin is predominantly used for the treatment of bacterial infections. Its active ingredient, minocycline hydrochloride, is known for its antibacterial properties that help in combating these infections.
Minocin, the antibacterial drug by Rempex, is covered by 2 significant patents. The last of these patents is set to expire on 12 May, 2031, which could open the pathway for generic versions of Minocin. Below are the details of the patent: